diabetestalk.net

Indian Diabetes Market Report

Indian Diabetes Market Report & Outlook For 2010-2015 Through Bharatbook.com

Indian Diabetes Market Report & Outlook For 2010-2015 Through Bharatbook.com

Bharatbook.com announces inclusion of latest report on "Indian Diabetes Market Report & Outlook For 2010-2015"(With around 51 Million diabetes patients, India promises to be amongst the most lucrative diabetes markets in the world. In 2009, the total sales of Insulin and Non-Insulin Anti-diabetics reached US$ 424 Million. Although, this represents just a fraction of the global sales, IMARC expects this market to surge in the future. In 2009, Non-Insulin Anti-diabetics occupied 72% of the total diabetes market. Biguanides represented the leading drug class with a 43% market share. In the next five years, IMARC expects newer classes such as DPP-IV Inhibitors and GLP-1 Agonists to drive the Non-Insulin Anti-diabetics market. From a market share of 6% in 2009, IMARC expects DPP-IV Inhibitors to occupy 17% of the total Non-Insulin Anti-diabetics market by 2015. Unlike Non-Insulin’s, the Insulin market in India was concentrated with the top five players occupying 96% of the total market. The Insulin market is expected to grow at a CAGR of 25% between 2010 and 2015, registering sales worth US$448 Million. During the next five years, the main drivers of this market will be the growth in the total drug treated population coupled with a much improved access and administration of Insulin. Report Highlights * A growing drug treated population coupled with the launch of several new drugs will drive the Indian diabetes market to US$1.4 Billion by 2015. * In 2009, the market for Non-Insulin Anti-diabetics was worth US$ 306 Million. This represented a highly fragmented market with USV being the leading player with a 14% share. * USV’s Glycomet GP (Glimepiride+Metformin) was the leading drug in the Non-Insulin Anti-diabetics market with sales worth nearly US$ 10.5 Million * IMARC ex Continue reading >>

Indian Pharmaceutical Industry

Indian Pharmaceutical Industry

Last Updated: December, 2017 The Indian pharmaceuticals market is the third largest in terms of volume and thirteenth largest in terms of value, and it accounts for 20 per cent in the volume terms and 1.4 per cent in value terms of the Global Pharmaceutical Industry as per a report by Equity Master. India is the largest provider of generic drugs globally with the Indian generics accounting for 20 per cent of global exports in terms of volume. Of late, consolidation has become an important characteristic of the Indian pharmaceutical market as the industry is highly fragmented. India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Presently over 80 per cent of the antiretroviral drugs used globally to combat AIDS (Acquired Immuno Deficiency Syndrome) are supplied by Indian pharmaceutical firms. The UN-backed Medicines Patent Pool has signed six sub-licences with Aurobindo, Cipla, Desano, Emcure, Hetero Labs and Laurus Labs, allowing them to make generic anti-AIDS medicine TenofovirAlafenamide (TAF) for 112 developing countries. The Indian pharma industry, which is expected to grow over 15 per cent per annum between 2015 and 2020, will outperform the global pharma industry, which is set to grow at an annual rate of 5 per cent between the same period!. The market is expected to grow to US$ 55 billion by 2020, thereby emerging as the sixth largest pharmaceutical market globally by absolute size, as stated by Mr Arun Singh, Indian Ambassador to the US. Branded generics dominate the pharmaceuticals market, constituting nearly 80 per cent of the market share (in terms of revenues). The sector is expected to generate 58,000 Continue reading >>

India Diabetes Industry Research And Forecasts To Fy'2016 - Shift Towards Modern Insulin Delivery Devices

India Diabetes Industry Research And Forecasts To Fy'2016 - Shift Towards Modern Insulin Delivery Devices

The report titled "India Diabetes Industry Research and Forecasts to FY'2016 - Shift towards Modern Insulin Delivery Devices" provides a comprehensive analysis on the market size of diabetes industry on the basis of number of diabetic patients in India, sales of anti-diabetic drugs and diabetes devices in India, market segmentation by Type 1 and Type 2 diabetic patients, Insulin and oral anti-diabetic drug market in India. The report also entails the size of diabetes testing devices and insulin delivery devices segments further categorized into test strips, glucose meters, lancets, vial and syringes, reusable insulin pens and prefilled pens. The report also covers competitive landscape and profiles of major players operating in the diabetes industry. India is the second largest diabetes-affected nation in the world after China (~ million), accounting for ~ million diabetic patients followed by the US (~ million) in 2011. India contributed maximum to regional mortality with ~ deaths caused due to diabetes in 2011. The most affected diabetic patients falls in the age group of 40-59 years which accounts about ~% of total diabetic population and the least affected age group is 20-39 accounting ~% of total diabetic patients in India. Despite a high prevalence rate of diabetes, the country spends merely about USD ~ million which is just 1% of the total diabetes spending worldwide. Indian anti-diabetic drugs market contributed around ~% of total global anti-diabetic drugs market. In FY'2008, the value of anti-diabetic drugs market in India was USD ~ million which grew up to USD ~ million in FY'2011. The most popular oral anti-diabetic drugs are biguanides, gliclazide, gliclazide with metformine, rosiglitazone and Pioglitazone of which biguanides contributed around ~% market sh Continue reading >>

India's Diabetics Have Poor Access To Insulin, Says Study

India's Diabetics Have Poor Access To Insulin, Says Study

Access to life-saving insulin for India's nearly 60 million diabetics is far lower than the World Health Organization's target of 80% says a new study1. For a country that is rushing to become the world's diabetic capital, this should be a matter of "serious public health concern," warn Abhishek Sharma and Warren Kaplan, authors of the study form the Boston University School of Public Health in the U.S. They are the first to analyze insulin availability in India's private sector that caters to majority of diabetes patients, who are forced to spend from their pockets due to the failure of national programmes to provide free health-care facilities. Unaffordable prices, excessive dependence on foreign-made insulin and an unholy nexus between Indian doctors and foreign manufacturers that force patients to buy expensive insulins instead of cheaper local brands, are among the barriers cited in the study for the patients' poor access to insulin. For this study, researchers surveyed the insulin products sold in select pharmacies in Delhi and interviewed private-sector insulin retailers and wholesalers. They found that Indian doctors do not trust local products and believe that insulin from foreign companies is better. Only 25% of surveyed pharmacies stocked Indian brands — a finding the study says is a sign of "public health failure." Recombinant human insulins have been produced since 1980s using genetically modified microbes. "Analogue" insulin, an altered form of recombinant insulin and 5-9 times costlier, came into the market over the past decade. Wholesalers acknowledged that though recombinant insulin is cheaper, doctors are increasingly prescribing "analogues" made by foreign companies. "Of the five wholesalers we interviewed, only one supplied insulin products made by Continue reading >>

India Faces Diabetes Explosion

India Faces Diabetes Explosion

NEW DELHI: India has done well in curbing stunting over the last decade, but the growing number of overweight people, particularly those prone to diabetes, may be a cause of concern, the Global Nutrition Report 2016, says. Though still home to one third of the world's 159 million stunted children aged below five years, India has witnessed a sharp decline in the prevalence of stunting, from 48% in 2006 to 38.7% in 2014. Stunting, defined by Unicef as the most prevalent form of under-nutrition, develops as a result of sustained poor dietary intake or repeated infections or both. "There is real hope that India can become a major part of the solution (to malnutrition). It almost doubled the rate of stunting reduction in the past 10 years compared with the previous decade," the report says. However, it also calls for urgent attention to tackle the rising percentage of the overweight in India, in particular the high rate of diabetes among them. It points out that the prevalence of adult diabetes in India was recorded at 9.5% in 2015, against a global average of 9%. According to the latest estimates of the World Health Organisation, the number of Indians with diabetes doubled from 32 million in 2000 to 63 million in 2013, and is projected to balloon to 101.2 million in the next 15 years. "India is in double jeopardy. It always had under nutrition, and (now) there is ever growing threat of over nutrition and diabetes. Public health policies must be strengthened to fight both, particularly the latter," said Dr Anoop Misra, chairman, FortisBSE -0.46 % C-DOC. The report also highlights India's growing burden of non-communicable diseases. It shows cardiovascular disease patients in India spent 30% of their annual family income on related healthcare. The report, a peer reviewed publ Continue reading >>

India Diabetes Devices Market - Growth, Trends, And Forecasts (2016 - 2021)

India Diabetes Devices Market - Growth, Trends, And Forecasts (2016 - 2021)

The Indian diabetes devices market has been estimated at USD XX billion in 2016 and is projected to reach USD XX billion by 2021, at a CAGR of XX% during the forecast period from 2016 to 2021. Diabetes care devices are the devices used to control the glucose levels in the blood. The main types of diabetes care devices include glucose monitoring devices and insulin delivery devices. The continuous glucose monitoring devices are increasingly widely used due to innovations and technological innovations. Diabetes is growing at an alarming rate in India, home to more than 65.1 million people with the disease, compared to 50.8 million in 2010. One main reason for the rise in the diabetic population is obesity. Obesity is reaching epidemic proportions among India's middle-class children and adolescents, as young people choose western fast food over traditional cuisine. India Diabetes Devices Market-Market Dynamics The Indian market is of more interest in the near future as the market is at a growing stage and is expected to dominate the market in the future, owing to the large patient pool in this region. This escalation is developing the need to analyze, review and forecast the growth of the diabetes device market. Owing to the rapid evolution of the market in the use of glucose monitoring devices, medical device companies that are able to launch new innovative equipment will be rewarded with huge benefits. The report details several factors driving and restraining the market. Some of these are listed below. Drivers Some of the factors contributing to the growth of the market are: Large patient pool suffering from diabetes Rapid innovation in developing new technologies Increased R&D in diabetes Increasing awareness Improving diagnosis & treatment rates Restraints Patent expi Continue reading >>

Indian Diabetes Market Research And Analysis – 2015-2022

Indian Diabetes Market Research And Analysis – 2015-2022

Pharmaceutical Market Reports has been published the new research report today. Market Insights The Indian diabetes market is estimated to grow with the CAGR of 20.5% during the period 2017-2022. The major factors that are augmenting the growth of the market are increase in the geriatric population of the India, urbanization and increasing prevalence of diabetes in the country. Additionally, rising obesity levels, innovation and development of new product for the diagnosis and treatment of diabetes and growing trend of the wearable devices and POC solution are also some of the major factors that are fuelling the growth of the Indian diabetes market. India has huge potential for the growth of the diabetes market. Diabetes is an expensive and rapidly growing health problem all over the world. In 2015, it is estimated that the approximately 370 million across the globe have diabetes, out of which more than 90% of the population have Type-II diabetes. India has the second largest number of diabetic’s population in the world. In 2015, about 60 million people India is suffering from diabetes. Moreover, 75 million people are in the risk to develop diabetes. These are the major factors that are attracting multinational companies to invest in India. Therefore increasing investment by the key players in the India are driving the growth of the diabetes market. Increasing geriatric population is also one of the major factors driving the growth of the diabetes market in India. In the year 2015, population aging 65 year or older is estimated to account for about 6% of the total population of the India i.e. 78 million, it is further estimated to reach 8.8% by the year 2030. Population aging 65 or older are more prone to diabetes. Therefore increasing geriatric population in India is Continue reading >>

Diabetes Drugs Market In India Grows 22% At $700 Mn In Fy’12

Diabetes Drugs Market In India Grows 22% At $700 Mn In Fy’12

Mumbai, June 18: In an indicator of the growing prevalence of diabetes in India, the domestic diabetes drugs market for FY’12 grew 22 per cent at $700 million, according to a Credit Suisse report. Estimates suggest that India is set to become the ’diabetes capital of the world’ with the number of people with diabetes is likely to swell to 70 million from present 40 million. “The diabetes, ophthalmic and derma have the higher mix of fastest-growing molecules in FY‘12. The therapy split of molecules grew by 30 percent, of which diabetes molecule grew 22 percent at $700 million,” Credit Suisse research analyst Anubhav Aggarwal told PTI here. The pharmaceutical industry is witnessing 25 percent growth in overall diabetes and 15 per cent in insulin segment, Mr Aggarwal said. Among other therapy molecules, cardiac grew by 20 per cent, pain and anti-invective 7 per cent, resp-acute 5 per cent, and oncology and gastro 3 per cent each. The Credit Suisse report on speciality pharmaceuticals said Sun Pharma, Glenmark and Lupin have the best overall portfolios in India. “Glenmark gets only one—fourth of its sales from chronic therapies and despite that it has the highest exposure in the fastest-growing molecules. Sun Pharma too has strong exposure to high-growth molecules and consistently gained market share across the segments. Lupin and Glenmark also continued to gain market shares in the highest growth segment, the report said. Among other leading pharma players, Dr Reddy’s, Cadila and Cipla have high exposure to slow-growing molecules, it said. Continue reading >>

Indian Diabetes Market Report Epidemiology, Patients, Prevalence, Oral Anti Diabetics, Insulin And Diagnostics - Reports Corner

Indian Diabetes Market Report Epidemiology, Patients, Prevalence, Oral Anti Diabetics, Insulin And Diagnostics - Reports Corner

Indian diabetes market report epidemiology, patients, prevalence, oral anti diabetics, insulin and diagnostics - Reports Corner 1. RCReports CornerIndian Diabetes Market Report: Epidemiology, Patients,Prevalence, Oral Anti-diabetics, Insulin and Diagnostics 2. DescriptionDescriptionReports Cornerwww.reportscorner.comIndia with over 63 million diabetics represents the worlds secondlargest diabetes population after China. The Indian population thathad faced under nutrition for a long time is now exposed to overnutrition and sedentary lifestyles. 3. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comIndia with over 63 million diabetics represents the worlds secondlargest diabetes population after China. The Indian population thathad faced under nutrition for a long time is now exposed to overnutrition and sedentary lifestyles. Coupled with a bad nutritionalhistory and the fact that Indians are genetically more vulnerable todiabetes compared to other population groups, Indias strugglewith diabetes is expected to be one of the biggest epidemics thecountry has ever witnessed.Indias diabetes statistics may ring alarm bells for the governmentand healthcare authorities, for drug and diagnosticmanufacturers, however, it represents a goldmine. Fuelled by acontinuous increase in the healthcare expenditures, the marketfor diabetes drugs and diagnostics is expanding robustly in thecountry. This is creating lucrative opportunities for globalhealthcare companies at a time when growth rates in the moredeveloped markets have declined. 4. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comIMARCs new report "Indian Diabetes Market Report:Epidemiology, Patients, Prevalence, Oral Anti-diabetics, Insulinand Diagnostics" provides an analytical and statistical insight intoth Continue reading >>

India Diabetes Market - Forecast To 2023

India Diabetes Market - Forecast To 2023

India Diabetes Market information, by Type (Type 1, Type 2, and Gestational diabetes), by Test (Random blood sugar test, Fasting blood sugar test, Oral glucose tolerance test, Initial glucose challenge test and others), by Devices (Blood glucose monitoring devices, Diabetes management devices, and others) by Treatment (Medications, Insulin therapy, Transplantation, Bariatric surgery and others) - Forecast to 2023 Study objectives of India Diabetes Market: To provide detailed analysis of the market structure along with forecast for the next 6 years of the various segments and sub-segments of the Indian Diabetes Market To provide insights about factors affecting the market growth To analyze the India Diabetes Market based on various factors - price analysis, supply chain analysis, Porters Five Forces analysis etc. To provide historical and forecast revenue of the market segments and sub-segments To provide detailed analysis of the market with respect to the current market size and future prospective To provide detailed analysis of the market for segments by type, by test, by devices, by treatment, and its sub-segments. To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the India Diabetes Market India Diabetes Market Share by Devices, 2016 (%): Market Scenario: Diabetes is a chronic metabolic disease that cause high blood sugar due to which body becomes incapable of producing insulin. According to World Health Organization (WHO), India had 69.2 million people living with Continue reading >>

Insulin Market In India 2016

Insulin Market In India 2016

India Anti-Diabetic Drug Market 4.5.2. New Report on Global and India Insulin Lispro Market 2016 Industry Trend and Forecast 2021 added to Orbisresearch.com store which has 79 The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The global human insulin market is expected to witness significant growth ... India, and Brazil. India Anti-Diabetic Drug Market Future Projections, FY2012-FY2016 4.5.3. Indian Diabetes Market Indian Insulin Market, Oral Antidiabetics Market and Diabetes Diagnostics Market Indian diabetes drug market is expected to reach $55.3 billion by 2017. MRS Research Group Global and India Insulin Lispro Market 2016 - Production, Sales, Supply, Demand, Analysis & Forecast to 2021 The report here talks about certain aspects of the Global and india insulin lispro industry 2016 market research report market which pronounces the future and present statistics of the market with respect to the trends in play. Can be ready in 2016: Tresiba (insulin ... A List of New Insulin Formulations Under Development ... but theres nothing market-ready. India harbors worlds largest population of diabetics and this made India a hotspot for foreign diabetes drug makers. Access to Insulin in India Constrained by Costs, Lack of Market Competition Posted on: October 14, 2016 Topics: diabetes, pharmaceuticals Most patients in India, including those with diabetes, seek health care in the private sector through out Global pharma looks to India: ... market Indias pharmaceuticals industry looks ... on Indias insulin dependence).22 The Company Profiles of Major Players in Insulin Market 4.6.1. This report analyses the prevalence of diabetes in India and evaluates the market for diabetes drugs (insulin and Continue reading >>

Insulin Market In India 2016

Insulin Market In India 2016

Indian diabetes drug market is expected to reach $55.3 billion by 2017. The main purpose of the of the study is to justify the occurrences in the Global and india insulin lispro industry 2016 market research report market by providing reader with useful and appropriate insights on the particulars of the market for the future scope of growth and available opportunities at the current state of the Global and india insulin lispro industry Five diabetes drugs in top-10 selling list ... pharma retail market had largely been dominated by anti-infectives and antibiotics in the past. Indian Diabetes Market Indian Insulin Market, Oral Antidiabetics Market and Diabetes Diagnostics Market India harbors worlds largest population of diabetics and this made India a hotspot for foreign diabetes drug makers. Featured: Diabetes Management Devices, Tools and Companies in India (2016) November 14, ... Diabetes Drugs Market in India and Indian Drug Makers. Access to Insulin in India Constrained by Costs, Lack of Market Competition Posted on: October 14, 2016 Topics: diabetes, pharmaceuticals Most patients in India, including those with diabetes, seek health care in the private sector through out 23-Aug-2016 | Zion Market Research. The report titled India Diabetes Industry Research and Forecasts to FY2016 Shift towards Modern Insulin Delivery Devices provides a comprehensive analysis on the market size of diabetes industry on the basis of number of diabetic patients in India, sales of anti-diabetic drugs and diabetes devices in India, market segmentation by Type 1 and Type 2 diabetic patients, Insulin and oral anti-diabetic drug market in India. This report analyses the prevalence of diabetes in India and evaluates the market for diabetes drugs (insulin and Oral anti-diabetics) and diagnost Continue reading >>

Indian Diabetes Market Report: Patients, Prevalence, Oral Antidiabetics, Insulin And Diagnostics

Indian Diabetes Market Report: Patients, Prevalence, Oral Antidiabetics, Insulin And Diagnostics

IMARC’s new report “Indian Diabetes Market Report: Patients, Prevalence, Oral Antidiabetics, Insulin and Diagnostics” provides an analytical and statistical insight into the Indian diabetes market. The report provides both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in India. The report has segmented the Indian diabetes market into three segments - Oral Antidiabetics, Insulin and Diabetes Diagnostics. For each of the aforementioned categories, the report provides historical and future market sales, performance of key classes and the performance of top players. The research study serves as an exceptional tool to understand the epidemiology, market trends, therapeutic structure, competitive structure and the outlook of the Indian diabetes market. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the Indian diabetes market in some form or the other. What we have achieved in this report: Comprehensive situation analysis of the Indian diabetes epidemiology and its dynamics: Focus of the Analysis: Historical, current and future prevalence of diabetes in India Historical, current and future prevalence of type-1 and type-2 diabetes in India Historical, current and future prevalence of diabetes in the urban and rural regions in India Historical, current and future prevalence of diabetes among males and females in India Historical, current and future prevalence of diabetes among various age groups in India Historical, current and future diagnosis rates for diabetes in India Historical, current and future drug treatment rates for diabetes in India Comprehensive situation analysis of the Indian Oral Antidiabetics mar Continue reading >>

Type 2 Diabetes Market (t2d) 2025 Insights In Epidemiology Forecast Report

Type 2 Diabetes Market (t2d) 2025 Insights In Epidemiology Forecast Report

Global and highly mature type 2 diabetics market is forecast to be worth $58.7 Billion by 2025 with epidemiologists forecasting an increase in the diagnosed prevalent cases of T2D in the 9MM, from 116,871,808 diagnosed prevalent cases in 2015 to 151,907,657 diagnosed prevalent cases in 2025, with an Annual Growth Rate (AGR) of 3%. Complete report on Type 2 Diabetes Epidemiology Forecast to 2025 of 69 pages with 10 tables and 7 figures is now available at . RnRMarketResearch.com adds "EpiCast Report: Type 2 Diabetes - Epidemiology Forecast to 2025" to its store providing an overview of the risk factors and global trends of type 2 diabetics market in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, China, and India). It includes a 10-year epidemiology forecast of T2D diagnosed prevalent cases segmented by age (in ten-year increments beginning at ages 20-30 years and ending at age 80 years and older), sex, and comorbidities including chronic kidney disease (CKD), cardiovascular disease (CVD), overweight/obesity, hypertension, and dyslipidemia in these nine markets. The projected increase in the diagnosed prevalent cases of type 2 diabetics market across all major regions covered in this analysis is attributed to the actual increase in the incidence of T2D along with the change in population demographics in the respective markets. This epidemiologists utilized country-specific diagnosed prevalence data for type 2 diabetics market across the 9MM. Additionally, the epidemiological forecast for the diagnosed prevalent cases of T2D in the 9MM is supported by nationally representative longitudinal historical data obtained from studies in respective countries published in peer-reviewed journals or national healthcare databases, which provide a detailed insight into the epid Continue reading >>

Indian Diabetes Market Share, Size And Forecast 2017-2022

Indian Diabetes Market Share, Size And Forecast 2017-2022

1. Copyright © IMARC. All Rights Reserved Indian Diabetes Market Report: 2017 - 2022 2. IMARC is a leading advisor on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise. IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results. Report DescriptionAbout IMARC Group 3. Report DescriptionReport Description and Highlights Indian Diabetes Market Encouraged by Obesity and Sedentary Lifestyle Over the past couple of decades, diabetes has affected as many as 70 Million of the Indian population. Some of the factors responsible for this include western influence on dietary habits, sedentary lifestyle, urbanisation, obesity, etc. As a result of this, the Indian diabetes market is expected to grow at 17% during 2017-2022. Diabetes, also known as hyperglycaemia, is caused when the glucose levels in the blood are higher than normal. With about 70 Million people suffering from the disease, India accounts for the world’s largest population of diabetic patients, and this Continue reading >>

More in diabetes